MX359947B - EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. - Google Patents

EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.

Info

Publication number
MX359947B
MX359947B MX2013010507A MX2013010507A MX359947B MX 359947 B MX359947 B MX 359947B MX 2013010507 A MX2013010507 A MX 2013010507A MX 2013010507 A MX2013010507 A MX 2013010507A MX 359947 B MX359947 B MX 359947B
Authority
MX
Mexico
Prior art keywords
interferon
patient
flu
severity
preparation
Prior art date
Application number
MX2013010507A
Other languages
English (en)
Spanish (es)
Other versions
MX2013010507A (es
Inventor
Deykin Aaron
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2013010507A publication Critical patent/MX2013010507A/es
Publication of MX359947B publication Critical patent/MX359947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
MX2013010507A 2011-03-15 2012-03-15 EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE. MX359947B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (2)

Publication Number Publication Date
MX2013010507A MX2013010507A (es) 2014-04-30
MX359947B true MX359947B (es) 2018-10-17

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010507A MX359947B (es) 2011-03-15 2012-03-15 EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.

Country Status (25)

Country Link
US (6) US9198955B2 (https=)
EP (1) EP2686002B1 (https=)
JP (2) JP6279905B2 (https=)
KR (1) KR102050339B1 (https=)
CN (1) CN103702680A (https=)
AU (1) AU2012229104B2 (https=)
BR (1) BR112013023609A8 (https=)
CA (1) CA2846786C (https=)
CY (1) CY1120176T1 (https=)
DK (1) DK2686002T3 (https=)
EA (1) EA028448B1 (https=)
ES (1) ES2666850T3 (https=)
HR (1) HRP20180621T1 (https=)
HU (1) HUE036931T2 (https=)
IL (1) IL228425A (https=)
LT (1) LT2686002T (https=)
MX (1) MX359947B (https=)
PL (1) PL2686002T3 (https=)
PT (1) PT2686002T (https=)
RS (1) RS57175B1 (https=)
SG (1) SG193446A1 (https=)
SI (1) SI2686002T1 (https=)
SM (1) SMT201800221T1 (https=)
WO (1) WO2012125809A1 (https=)
ZA (1) ZA201306933B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686002B1 (en) * 2011-03-15 2018-01-24 Biogen Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP3092305B1 (en) * 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
US11266344B2 (en) 2016-09-21 2022-03-08 Samsung Electronics Co., Ltd. Method for measuring skin condition and electronic device therefor
WO2022069250A1 (en) * 2020-09-30 2022-04-07 Koninklijke Philips N.V. Methods and systems for performing dose titration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
EP1605992B1 (en) * 2003-01-30 2018-11-21 Becton, Dickinson and Company Holder with safety shield for a drug delivery device
JP4988562B2 (ja) * 2004-06-01 2012-08-01 アレス トレーディング ソシエテ アノニム 安定化したインターフェロン液体製剤
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
CA2672284C (en) * 2006-12-18 2014-08-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
JP2012530721A (ja) * 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
EP2686002B1 (en) * 2011-03-15 2018-01-24 Biogen Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Also Published As

Publication number Publication date
CY1120176T1 (el) 2018-12-12
DK2686002T3 (en) 2018-04-30
ZA201306933B (en) 2016-07-27
BR112013023609A2 (pt) 2016-12-06
US20220280610A1 (en) 2022-09-08
JP2018030847A (ja) 2018-03-01
NZ616536A (en) 2015-10-30
JP6279905B2 (ja) 2018-02-14
LT2686002T (lt) 2018-05-10
EA201301024A1 (ru) 2014-03-31
IL228425A (en) 2017-08-31
KR102050339B1 (ko) 2019-11-29
CA2846786C (en) 2022-05-17
EA028448B1 (ru) 2017-11-30
US20250276042A1 (en) 2025-09-04
US20160101157A1 (en) 2016-04-14
EP2686002A1 (en) 2014-01-22
SG193446A1 (en) 2013-10-30
IL228425A0 (en) 2013-12-31
ES2666850T3 (es) 2018-05-08
AU2012229104A1 (en) 2013-10-03
US20170360890A1 (en) 2017-12-21
US9198955B2 (en) 2015-12-01
RS57175B1 (sr) 2018-07-31
KR20140038383A (ko) 2014-03-28
HUE036931T2 (hu) 2018-08-28
WO2012125809A1 (en) 2012-09-20
US10500254B2 (en) 2019-12-10
CN103702680A (zh) 2014-04-02
SI2686002T1 (en) 2018-06-29
NZ712273A (en) 2016-09-30
US20120237479A1 (en) 2012-09-20
HRP20180621T1 (hr) 2018-07-27
JP2014508174A (ja) 2014-04-03
PL2686002T3 (pl) 2018-10-31
SMT201800221T1 (it) 2018-07-17
EP2686002B1 (en) 2018-01-24
PT2686002T (pt) 2018-04-23
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
MX2013010507A (es) 2014-04-30
US20200046804A1 (en) 2020-02-13
JP6522069B2 (ja) 2019-05-29
AU2012229104B2 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
IN2014MN00333A (https=)
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
BR112015027297A8 (pt) administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
MX359947B (es) EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CU24209B1 (es) Composición farmacéutica en forma de una suspensión oral que comprende una fracción flavonoica y goma de xantano
BR112015010651A2 (pt) composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos
BR112014015314A8 (pt) composição farmacêutica não entérica compreendendo crofelemer
EA201300096A1 (ru) Лекарственный препарат, обладающий антибактериальным, противоязвенным и иммуномодулирующим действием
CO2018013792A2 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo
MX2015009681A (es) Un medicamento combinado que comprende finilefrina y paracetamol.
DK2609926T3 (da) Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat
CL2013003671A1 (es) Composicion y combinacion farmaceutica que comprende ketorolaco y meloxicam; proceso para preparar la composicion; uso en el tratamiento de la inflamacion y el dolor.
EA201201093A1 (ru) Противовоспалительное средство для лечения контактного дерматита

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: PFIZER, INC.

GB Transfer or rights

Owner name: BIOGEN MA INC.

FG Grant or registration